Cue Biopharma, Inc.CUENASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

9 analysts·Limited coverage

100%

Rating Distribution

Strong Buy

00%

Buy

9100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 1196% higher.

Bear Case

$2.00

+498%

Consensus

$4.33

+1196%

Bull Case

$7.00

+1995%

Price Range9 analysts

Low

Consensus

High

$2.00

$7.00

Current Target

Current Price

$0.33

Upside to Target

$4.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.47(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+95.45%

EPS—

FY2028

Rev+406.51%

EPS—

FY2029

Rev+179.43%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+11.7%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 15, 2024Jefferies

Cue Biopharma (CUE) PT Lowered to $4 at Jefferies

Target:$4.00

+211.3%from $1.28

Jul 26, 2024JMP Securities

Cue Biopharma price target lowered to $2 from $15 at JMP Securities

Target:$2.00

+184.4%from $0.70

Mar 13, 2024Jefferies

Jefferies Starts Cue Biopharma (CUE) at Buy, 'Following Nature's "Cues" W/ Targeted IL-2 Therapy'

Target:$6.00

+179.1%from $2.15

Nov 20, 2022Piper Sandler

Cue Biopharma initiated with an Overweight at Piper Sandler

Target:$7.00

+117.4%from $3.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance